XTX Topco Ltd Acquires New Shares in Humana Inc. (NYSE:HUM)

XTX Topco Ltd bought a new position in Humana Inc. (NYSE:HUM - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,452 shares of the insurance provider's stock, valued at approximately $1,727,000.

A number of other institutional investors also recently modified their holdings of the stock. State Street Corp raised its holdings in Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider's stock valued at $1,701,582,000 after buying an additional 53,272 shares in the last quarter. FMR LLC grew its holdings in Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock valued at $1,073,387,000 after purchasing an additional 643,291 shares during the last quarter. Pzena Investment Management LLC raised its position in shares of Humana by 8.1% in the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider's stock valued at $793,830,000 after purchasing an additional 187,903 shares during the period. Davis Selected Advisers lifted its stake in shares of Humana by 16.1% in the second quarter. Davis Selected Advisers now owns 2,311,362 shares of the insurance provider's stock worth $863,640,000 after buying an additional 321,233 shares during the last quarter. Finally, Marshall Wace LLP boosted its holdings in shares of Humana by 118.9% during the 2nd quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider's stock worth $532,564,000 after buying an additional 774,085 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Price Performance

NYSE HUM traded down $1.33 on Friday, hitting $281.73. 1,751,061 shares of the company were exchanged, compared to its average volume of 1,590,764. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $488.89. The firm has a 50 day moving average of $272.68 and a two-hundred day moving average of $326.83. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $33.92 billion, a P/E ratio of 24.95, a P/E/G ratio of 2.27 and a beta of 0.53.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating analysts' consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. On average, equities analysts predict that Humana Inc. will post 16.14 EPS for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.26%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana's dividend payout ratio (DPR) is presently 31.36%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HUM. Leerink Partnrs lowered shares of Humana from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 2nd. Bank of America upgraded Humana from an "underperform" rating to a "neutral" rating and increased their target price for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Oppenheimer dropped their price target on Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a research report on Thursday, October 3rd. Jefferies Financial Group cut Humana from a "buy" rating to a "hold" rating and reduced their price objective for the company from $519.00 to $253.00 in a research report on Monday, October 7th. Finally, Wells Fargo & Company decreased their price target on shares of Humana from $387.00 to $290.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Humana has a consensus rating of "Hold" and a consensus price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.